About Elena
Contact Elena


Serving Parker, Centennial & the Denver Area


Cancer surpasses cardiovascular disease as leading cause of death among U.

The most effective approaches for reducing the cancers burden in these underserved communities make use of tailored, appropriate interventions culturally, such as for example patient navigation, to increase access to medical services. said Rebecca Siegel, MPH, lead writer of the report.. Cancer surpasses cardiovascular disease as leading cause of death among U.S. Hispanics A new report from American Cancer Society researchers finds that despite declining death rates, cancer has surpassed heart disease as the leading reason behind death among Hispanics in the U.S. In ’09 2009, the most recent year that actual data can be found, 29,935 folks of Hispanic origin in the U.S. Died of cancer, in comparison to 29,611 deaths from heart disease. Among non-Hispanic whites and African People in america, heart disease remains the number one cause of death. Continue reading

As we mature.

Going back again to the mind scans, Ofen found that the enriched thoughts also correlated with more extreme activation in a particular region of the PFC. ‘We found no modification with age for recollections without context,’ Ofen clarifies. ‘All of the maturation is definitely in thoughts with context. Our findings suggest that as we mature, we’re able to create even more rich memories contextually, and that ability evolves with a more mature PFC.’ Susan Whitefield-Gabrieli, a study associate at MIT’s McGovern Institute, contributed to the extensive research, in addition to researchers from Harvard University, New York University, and the University of California, Berkeley. Continue reading

Arrayit achieves technological breakthrough in microarray production Arrayit Company.

Arrayit achieves technological breakthrough in microarray production Arrayit Company , a life sciences and healthcare technology leader, today announced that the business has made a technological breakthrough in the quickness and efficiency by which it manufactures its proprietary microarrays, which are tiny glass substrates which contain rows and columns of printed spots used for scientific research and molecular diagnostics. The advance allows precise printing of as much as 2 highly pharmacy details .4 million microarrays each year with an individual robotic workstation, a substantial increase over the business’s current capacity of 640,000 microarrays per instrument annually. Continue reading

These conditions happen when the testis or ovary will not develop properly in the embryo.

‘To date, we realize of just a small number of genes that are involved in gonad development, and may only diagnose about 20 percent of DSD sufferers,’ he said. ‘Based on our research, we believe mutation of the MAP3K1 gene could possibly be responsible for an additional 20 percent of XY DSD instances. This is a major breakthrough as the MAP3K1 gene provides brand-new insights into regular testis development and significantly increases the quantity of DSD instances we can diagnose later on.’ The study, published today in the American Journal of Individual Genetics, was undertaken in collaboration with the Women’s and Children’s Hospital, Adelaide, NY University School of Medicine, MRC Mammalian Genetics Unit, UK, Center Hospitalier Universitaire de Nantes, France.. Continue reading

Will collaborate to develop XmAb5871.

Amgen and Xencor Enter Choice Deal to Co-Develop Xencor’s Novel Antibody for Autoimmune Diseases Amgen and Xencor, Inc effect of the tabs . Will collaborate to develop XmAb5871, an Fc – manufactured monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 happens to be in late-stage preclinical development for the treating autoimmune diseases. Under the terms of the contract, Amgen gets the option to an exclusive worldwide license following a completion of a pre-defined Phase 2 research. Xencor will lead all clinical development until that right time. Xencor shall receive an up-front and early advancement milestone payments. If Amgen does workout its option, Amgen shall assume responsibility for upcoming development, Xencor shall receive an option-exercise fee which, combined with up-front and early development milestones, will total $75 million, and Xencor could receive up to yet another $425 million in scientific, regulatory and commercialization milestone payments. Continue reading